Composition and method for treatment of depression and psychosis in humans
作者： Daniel C. Javitt
DOI:
关键词:
摘要: Compositions and methods for the treatment of depression psychoses in humans are disclosed. More particularly, invention is directed to formulations containing antipsychotic and/or antidepressant medications also an NMDAR antagonist. The present Invention Is tor suffering from other psychoses, including, schizophrenia, by administration inventive compositions effective amounts.
lens.org 参考文章(61)
P.S Sachdev, M Brüne, Animal models of acute drug-induced akathisia – a review Neuroscience & Biobehavioral Reviews. ,vol. 24, pp. 269- 277 ,(2000) , 10.1016/S0149-7634(99)00069-X
I. Gaisler-Salomon, L. Diamant, C. Rubin, I. Weiner, Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered Psychopharmacology. ,vol. 196, pp. 255- 267 ,(2008) , 10.1007/S00213-007-0960-3
Ewa Poleszak, Piotr Wlaź, Bernadeta Szewczyk, Aleksandra Wlaź, Regina Kasperek, Andrzej Wróbel, Gabriel Nowak, A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice Journal of Neural Transmission. ,vol. 118, pp. 1535- 1546 ,(2011) , 10.1007/S00702-011-0630-9
Kay Redfield Jamison, Suicide and bipolar disorder. The Journal of Clinical Psychiatry. ,vol. 61, pp. 47- 51 ,(2000) , 10.4324/9781315054308-12
Gerard J Marek, Raul Martin-Ruiz, Allyson Abo, Francesc Artigas, The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology. ,vol. 30, pp. 2205- 2215 ,(2005) , 10.1038/SJ.NPP.1300762
Mary J. Tanga, Ruin Moaddel, Marc C. Torjman, Michael E. Goldberg, Irving W. Wainer, Carlos A. Zarate, Michel Bernier, The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain ,(2012)
Guochuan Emil Tsai, Joseph T. Coyle, Methods for treating neuropsychiatric disorders ,(1999)
Joseph R. Moskal, Methods of treating depression and other related diseases ,(2013)
Mark R. Brann, Robert E. Davis, Allan K. Uldam, Carl-Magnus A. Andersson, David M. Weiner, Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ,(2004)
Paul A. Ardayfio, Mark J. Benvenga, Stephen F. Chaney, Patrick L. Love, John Catlow, Steven P. Swanson, Gerard J. Marek, The 5-Hydroxytryptamine2A Receptor Antagonist R-(+)-α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) Attenuates Impulsivity after Both Drug-Induced Disruption (Dizocilpine) and Enhancement (Antidepressant Drugs) of Differential-Reinforcement-of-Low-Rate 72-s Behavior in the Rat Journal of Pharmacology and Experimental Therapeutics. ,vol. 327, pp. 891- 897 ,(2008) , 10.1124/JPET.108.143370